5x broker valuation of 33c, page-23

This is an important question you asked and fortunately we have a good answer!

My understanding is that the company received the whole data set and excluded the cases that weren't relevant. Thus you have the total set of 169 patients in the control arm of the VenUS III trial reduced to just the 49 used in the FTT control curve. I've been told they went through patient by patient and mapped them to Margolis scores to ensure consistency.